Site icon Market Globalist

Why The GALT Stock Rose Nearly 35% During Last Session?

PRGS Stock

PRGS Stock

At the end of Tuesday’s regular trading session, Galectin Therapeutics Inc. (NASDAQ: GALT) closed its shares at $1.80 up 34.85% or $0.73. The Galectin stock recorded a high volume of 18.09 million shares, compared to the average daily volume of 304.27K shares. GALT stock skyrocketed after launching a website designed for chronic diseases.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

What is the website for?

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


The Galectin Therapeutics is dedicated to developing new therapies to help patients struggling with liver problems and cancer. GALT’s lead drug belapectin is a carbohydrate-based drug that interacts with the galectin-3 protein, which plays a role in multiple degenerative diseases, including inflammatory, fibrotic and malignant. Development revolves around the non-alcoholic steatohepatitis (NASH) with cirrhosis, the severe form of NASH-related fibrosis.

Read More, a dedicated trial website launched by Galectin Therapeutics, came online yesterday.

What GALT is eyeing on?

With the NAVIGATE Study, the goal of Galectin Therapeutics (GALT) is to prevent the development of esophageal varices, which have been linked to more serious complications of cirrhosis related to NASH.

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

Exit mobile version